S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:RIGL

Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis

$1.49
+0.07 (+4.93%)
(As of 03/27/2024 ET)
Today's Range
$1.40
$1.50
50-Day Range
$1.12
$1.57
52-Week Range
$0.71
$1.96
Volume
679,932 shs
Average Volume
1.48 million shs
Market Capitalization
$261.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.05

Rigel Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
238.9% Upside
$5.05 Price Target
Short Interest
Bearish
2.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.49mentions of Rigel Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.06) to $0.03 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.87 out of 5 stars

Medical Sector

718th out of 939 stocks

Pharmaceutical Preparations Industry

323rd out of 422 stocks

RIGL stock logo

About Rigel Pharmaceuticals Stock (NASDAQ:RIGL)

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

RIGL Stock Price History

RIGL Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
RIGL Apr 2024 3.000 call
Rigel Pharma Names Rojkjaer EVP, Chief Medical Officer
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals: Q4 Earnings Insights
Rigel Pharmaceuticals Inc. Q4 Earnings Summary
Q4 2023 Rigel Pharmaceuticals Inc Earnings Call
RIGL Mar 2024 1.500 put
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
See More Headlines
Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
3/27/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RIGL
CUSIP
76655960
Employees
147
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$5.05
High Stock Price Target
$15.00
Low Stock Price Target
$1.25
Potential Upside/Downside
+238.9%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-25,090,000.00
Pretax Margin
-21.47%

Debt

Sales & Book Value

Annual Sales
$116.88 million
Book Value
($0.16) per share

Miscellaneous

Free Float
164,101,000
Market Cap
$261.32 million
Optionable
Optionable
Beta
0.96

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Raul R. Rodriguez (Age 63)
    President, CEO & Director
    Comp: $1.09M
  • Mr. Dean L. Schorno CPA (Age 61)
    Executive VP & CFO
    Comp: $696.67k
  • Mr. Raymond J. Furey J.D. (Age 56)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $593.46k
  • Mr. David A. Santos (Age 61)
    Executive VP & Chief Commercial Officer
    Comp: $681.63k
  • Mr. Joseph Lasaga (Age 49)
    Executive Vice President of Corporate Development
  • Ms. Julie Patel
    Senior VP of Human Resources
  • Dr. Esteban S. Masuda (Age 62)
    Executive Vice President of Research
    Comp: $537.21k
  • Mr. Tarek Sallam
    Vice President of Marketing

RIGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Rigel Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RIGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RIGL, but not buy additional shares or sell existing shares.
View RIGL analyst ratings
or view top-rated stocks.

What is Rigel Pharmaceuticals' stock price target for 2024?

5 brokers have issued twelve-month target prices for Rigel Pharmaceuticals' stock. Their RIGL share price targets range from $1.25 to $15.00. On average, they anticipate the company's share price to reach $5.05 in the next year. This suggests a possible upside of 238.9% from the stock's current price.
View analysts price targets for RIGL
or view top-rated stocks among Wall Street analysts.

How have RIGL shares performed in 2024?

Rigel Pharmaceuticals' stock was trading at $1.45 at the beginning of the year. Since then, RIGL stock has increased by 2.8% and is now trading at $1.49.
View the best growth stocks for 2024 here
.

Are investors shorting Rigel Pharmaceuticals?

Rigel Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 4,940,000 shares, an increase of 32.1% from the February 29th total of 3,740,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is presently 4.5 days.
View Rigel Pharmaceuticals' Short Interest
.

When is Rigel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our RIGL earnings forecast
.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.04. The biotechnology company had revenue of $28.13 million for the quarter, compared to the consensus estimate of $27.83 million. During the same quarter last year, the business posted ($0.11) EPS.

What guidance has Rigel Pharmaceuticals issued on next quarter's earnings?

Rigel Pharmaceuticals updated its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $35.7 million-$35.7 million, compared to the consensus revenue estimate of $29.8 million.

What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?

6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (9.81%), Vanguard Group Inc. (5.13%), Vanguard Group Inc. (5.11%), Voya Investment Management LLC (1.20%), Assenagon Asset Management S.A. (1.14%) and Northern Trust Corp (0.88%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez.
View institutional ownership trends
.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RIGL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners